Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov Sells 2,431 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov sold 2,431 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $9.11, for a total value of $22,146.41. Following the completion of the sale, the chief executive officer now owns 187,471 shares in the company, valued at approximately $1,707,860.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Rosty Raykov also recently made the following trade(s):

• On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.75, for a total transaction of $476,225.00.
• On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.78, for a total transaction of $437,495.52.

Fennec Pharmaceuticals Price Performance

FENC stock remained flat at $9.09 during trading hours on Thursday. 94,401 shares of the company’s stock were exchanged, compared to its average volume of 113,755. The company’s fifty day moving average is $10.07 and its 200-day moving average is $9.49. Fennec Pharmaceuticals Inc has a 12-month low of $6.30 and a 12-month high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. As a group, equities research analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FENC has been the subject of a number of recent research reports. Craig Hallum increased their price objective on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. HC Wainwright increased their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, April 4th. Finally, Wedbush restated an “outperform” rating and issued a $16.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

Institutional Trading of Fennec Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its holdings in shares of Fennec Pharmaceuticals by 107.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after purchasing an additional 1,578 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Fennec Pharmaceuticals during the 3rd quarter worth about $50,000. Jump Financial LLC acquired a new position in Fennec Pharmaceuticals in the 4th quarter valued at about $158,000. BNP Paribas Financial Markets grew its stake in Fennec Pharmaceuticals by 67.7% in the 1st quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock valued at $364,000 after buying an additional 13,223 shares during the last quarter. Finally, Eudaimonia Advisors LLC raised its holdings in Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock valued at $367,000 after acquiring an additional 15,556 shares during the period. Institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.